A Single Arm, Single-centre, Open-label, Exploratory Trial of Recombinant Interleukin-21 Administered Subcutaneously for 4 Weeks as Neo-adjuvant Treatment Prior to Sentinel Lymph Node/Complete Lymph Node Dissection Followed by 8 Weeks of Adjuvant Treatment in Subjects With Stage III Malignant Melanoma
Phase of Trial: Phase II
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Denenicokin (Primary)
- Indications Cancer metastases; Malignant melanoma
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 04 Aug 2008 Status changed from suspended to terminated as reported by ClinicalTrials.gov.
- 19 Feb 2008 New trial record.